Do you want to link to this Amgen Site and leave Amgen.co.kr?
YOU ARE NOW LEAVING AMGEN KOREA'S WEB SITE. Amgen Korea takes takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.
Repatha® Inj. Pre-filled pen
Product Name (Korean) 레파타®주 프리필드펜
Product Name (English) Repatha® Inj. Pre-filled pen
Active Ingredient (Korean) 에볼로쿠맙
Active Ingredient (English) evolocumab
API content 140 mg/1.0 mL
Excipients Proline, Acetic acid, glacial, Polysorbate 80, Sodium hydroxide, Water for injection, Sterilized needle
Treatment Anti-atherosclerotic agent
Hypercholesterolemia and mixed dyslipidemia
THIS DRUG is indicated in adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant.
Homozygous Familial Hypercholesterolemia
THIS DRUG is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolemia (HoFH) in combination with other lipid-lowering therapies (e.g., statins, LDL apheresis).
Atherosclerotic cardiovascular disease
THIS DRUG is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies.